A randomised controlled trial comparing the effect of adjuvant intrathecal 2 mg midazolam to 20 micrograms fentanyl on postoperative pain for patients undergoing lower limb orthopaedic surgery under spinal anaesthesia by Codero, Francis et al.
eCommons@AKU
Anaesthesiology, East Africa Medical College, East Africa
March 2016
A randomised controlled trial comparing the effect
of adjuvant intrathecal 2 mg midazolam to 20
micrograms fentanyl on postoperative pain for
patients undergoing lower limb orthopaedic
surgery under spinal anaesthesia
Francis Codero
Aga Khan University
Vitalis Mung’ayi
Aga Khan University, vitalis.mung'ayi@aku.edu
Sharif Thikra
Aga Khan University
Follow this and additional works at: http://ecommons.aku.edu/eastafrica_fhs_mc_anaesth
Part of the Anesthesiology Commons
Recommended Citation
Codero, F., Mung’ayi, V., Thikra, S. (2016). A randomised controlled trial comparing the effect of adjuvant intrathecal 2 mg midazolam
to 20 micrograms fentanyl on postoperative pain for patients undergoing lower limb orthopaedic surgery under spinal anaesthesia.
African health sciences, 16(1), 282-291.
Available at: http://ecommons.aku.edu/eastafrica_fhs_mc_anaesth/8
A randomised controlled trial comparing the effect of  adjuvant intrathecal 
2 mg midazolam to 20 micrograms fentanyl on postoperative pain for patients 
undergoing lower limb orthopaedic surgery under spinal anaesthesia.
Codero Francis, Mung’ayi Vitalis, Sharif  Thikra
Department of  Anaesthesia, Aga Khan University, East Africa  
Abstract
Background: Intrathecal adjuvants are added to local anaesthetics to improve the quality of  neuraxial blockade and prolong the 
duration of  analgesia during spinal anaesthesia. Used intrathecally, fentanyl improves the quality of  spinal blockade as compared 
to plain bupivacaine and confers a short duration of  post-operative analgesia. Intrathecal midazolam as an adjuvant has been 
used and shown to improve the quality of  spinal anaesthesia and prolong the duration of  post-operative analgesia. No studies 
have been done comparing intrathecal fentanyl with bupivacaine and intrathecal 2 mg midazolam with bupivacaine.
Objective: To compare the effect of  intrathecal 2mg midazolam to intrathecal 20 micrograms fentanyl when added to 2.6 ml 
of  0.5% hyperbaric bupivacaine, on post-operative pain, in patients undergoing lower limb orthopaedic surgery under spinal 
anaesthesia.
Methods: A total of  40 patients undergoing lower limb orthopaedic surgery under spinal anaesthesia were randomized to two 
groups.
Group 1: 2.6mls 0.5% hyperbaric bupivacaine with 0.4mls (20micrograms) fentanyl
Group 2: 2.6mls of  0.5% hyperbaric bupivacaine with 0.4mls (2mg) midazolam
Results: The duration of  effective analgesia was longer in the midazolam group (384.05 minutes) as compared to the fentanyl 
group (342.6 minutes). There was no significant difference (P 0.4047). The time to onset was significantly longer in midazolam 
group 17.1 minutes as compared to the fentanyl group 13.2 minutes (P 0.023). The visual analogue score at rescue was signifi-
cantly lower in the midazolam group (5.55) as compared to the fentanyl group 6.35 (P - 0.043). 
Conclusion: On the basis of  the results of  this study, there was no significant difference in the duration of  effective analgesia 
between adjuvant intrathecal 2 mg midazolam as compared to intrathecal 20 micrograms fentanyl for patients undergoing lower 
limb orthopaedic surgery.
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Introduction
Acute postoperative pain is one of  the most common 
postoperative problems, with an incidence up to 70% 
in certain categories of  surgical patients1. Apfelbaum et 
al2 conducted a national survey in the United States and 
concluded that, acute post-operative pain continues to be 
undermanaged with up to 60% of  patients experiencing 
moderate to severe pain at hospital discharge. A recent 
study carried out at the Aga Khan University hospital in-
vestigated the incidence of   post-operative pain after day 
care surgery and concluded, that 56% of  patients suffer 
from moderate to severe pain after day care surgery3.
 
Acute  post-operative pain is a complex physiological re-
action to tissue injury which may result in unpleasant, un-
wanted sensory and emotional experiences4. It can result 
in delayed healing, delayed mobilization and increased 
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risk of  myocardial infarction or ischemia, risk of  tachy-
cardia and dysrhythmia. Other published reports indicate 
that  post-operative pain can lead to thromboembolic 
events, peripheral vasoconstriction, and metabolic acido-
sis5,6. Controlling post-operative pain has the potential to 
allow for earlier hospital discharge and may improve the 
patient's ability to tolerate physical therapy.
 
In the past few years various pharmacological and non-
pharmacological methods have been introduced to pro-
vide post-operative pain-relief. Systemic analgesics and 
conventional pain treatment modalities are effective in 
controlling  post-operative pain for majority of  patients. 
However, many other patients such as those with com-
plex trauma, and extensive injuries, require more aggres-
sive therapy to directly modulate pain transmission in the 
central nervous system; and a high dose of  systemic anal-
gesics may cause significant side effects such as alteration 
in mental processes, respiratory depression, and other 
cardiovascular instability.
The use of  intrathecal opioids in controlling post-oper-
ative pain has developed from an understanding for the 
role of  the spinal cord for modulating and processing no-
ciceptive stimuli, and the discovery of  opioid receptors in 
the spinal cord7. Several agents have been administered 
epidurally and intrathecally with and without local an-
aesthetic; such as opioids, benzodiazepines, neostigmine, 
clonidine, non-steroidal anti- inflammatory agents, vaso-
constrictors. The objective of  adding such agents is to 
provide more adequate analgesia, reduce the use of  oral 
analgesics with unwanted side effects, and to prolong the 
duration of  analgesia.
 
A vast number of  researchers have demonstrated the effi-
cacy of  intrathecal administration of  opioids such as fen-
tanyl and other agents such as midazolam in controlling 
post-operative pain8–11. Most of  those studies have dem-
onstrated benefits and side effects using different doses 
of  fentanyl and midazolam in controlling  post-operative-
pain8,10–12. Only one recent study by Talwar et al in 2008 
has been done to compare fentanyl 20 micrograms with 
1mg midazolam in which they investigated the net effect 
on  post-operative pain and side effects20.
Intrathecal opioids are associated with numerous com-
plications including respiratory depression, urinary re-
tention, pruritus, nausea and vomiting. The most feared 
complication is respiratory depression. The mechanism 
is through the rostral spread immediately after injection 
and with fentanyl and sufetanyl occurs within 20-30 min-
utes after injection. Evidence from small controlled stud-
ies and large observational studies13 show an incidence 
of  0.07%-0.49% clinically significant, dose dependent, 
and non-drug specific respiratory depression. Pruritus is 
the most common complication with incidence of  30-
100%14,15 and the management requires the administra-
tion of  opioid antagonists naloxone and naltrexone16,17 
which in larger doses may reverse the analgesic effect17.
There has been much recent attention towards the use 
of  benzodiazepine midazolam as an intrathecal drug in 
treatment of  acute and chronic pain18.
A study conducted by Kim et al19 however compared var-
ious doses of  intrathecal midazolam 1mg  and 2 mg plain 
0.5% hyperbaric bupivacaine, and found that time to first 
analgesia was significantly greater in the intrathecal group 
compared to plain bupivacaine and even more so for the 
2 mg group.
Based on the above stated author’s reviews it seems that 2 
mg intrathecal midazolam has an obvious advantage over 
1mg intrathecal midazolam as far as the density of  the 
neural blockade and duration of  postoperative analgesia.
Shadangi et al26 compared the effects of  intrathecal bupi-
vacaine with or without 2 mg midazolam and concluded 
that the addition of  preservative-free midazolam to bu-
pivacaine resulted in prolonged  post-operative analgesia 
without increasing motor block.
 The purpose of  this study is to compare the effect of  in-
trathecal bupivacaine with 2mg midazolam to intrathecal 
bupivacaine with 20 micrograms fentanyl on  post-opera-
tive pain for patients undergoing lower limb orthopaedic 
surgery under spinal anaesthesia.
Methods
The study was performed following approval from the 
Department of  Anaesthesia and the Research and Re-
search Ethical Committees of  the Aga Khan University.
Eligible patients were recruited after having signed an in-
formed consent, which clearly stated that it is a research 
study being conducted and that their information will be 
kept confidential and may be published. The patients were 
made to understand that they would receive health care 
as all other patients who came to theatre, and that they 
would not be denied care if  they declined to participate 
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in the study. For those who did not understand English 
the above information on the pain scale and instructions 
were explained in Swahili by the principal investigator 
and further data collection by the research assistants were 
done in Swahili.
An explanation on the study procedure was given to the 
patient both verbally and using a written form. It was also 
made clear there shall be no direct benefit to the patient 
arising from participation in the study, but that the results 
could be used to change local practice in the future. There 
were no added expenses to the patient.
The patients voluntarily signed the consent form and 
were recruited in the pre-anaesthesia review before com-
ing to the operating theatres.
This was a prospective single blinded randomized con-
trolled trial. The study was conducted at Aga Khan Uni-
versity hospital, Nairobi; a tertiary not for profit hospital 
with a bed capacity of  250 beds and postgraduate medical 
education programs in various disciplines. Since Nairobi 
is a cosmopolitan city, the patients served by this hospital 
cut across most racial groups present within the country. 
Patients were recruited from the outpatient pre-anaesthe-
sia clinics and as well inpatients from the wards.
The target population included all patients admitted for 
lower limb orthopaedic surgery at the Aga Khan Univer-
sity Hospital, Nairobi. The sample population included 
all ASA I, II and III patients scheduled for theatre for 
lower limb orthopaedic surgery between October 2012 
and January 2013.
 
Sample size calculation was based on the expected differ-
ence in mean duration of  analgesia between intrathecal 
midazolam and fentanyl effect.  Sample size formula for 
comparing two means was used to determine the required 
sample size.
The reported mean duration of  block for fentanyl is 296 
(sd=73.64)20 and for midazolam 2mg is 399 (sd=60)21. 
Using this information in the formula assuming 5% sig-
nificance level and power of  90%, the required sample 
size was 20 patients in each group (total of  40 patients).
A sample size of  40 patients was determined as sufficient 
to demonstrate a 103 minute mean difference in the du-
ration of  effective analgesia between patients undergo-
ing spinal anaesthesia with adjuvant 2mg midazolam and 
those with adjuvant fentanyl at the Aga Khan University 
hospital. The study was powered at 90%. Type 1 error 
was set at 0.05. The above formula was used since the aim 
of  the study was to determine the mean difference in the 
duration of  effective analgesia between the two intrathe-
cal adjuvant medications.
Simple randomization was done using a computer pro-
gram; the principal investigator generated a random se-
quence of  numbers. Each of  the random numbers was 
sequentially assigned to either;
Group 1; 2.6mls 0.5% hyperbaric bupivacaine with 0.4mls 
(20micrograms) fentanyl
Group 2; 2.6mls of  0.5% hyperbaric bupivacaine with 
0.4mls (2mg) midazolam
At the pre-operative visit, an anaesthesiologist and /or 
trained research nurse familiarized the patients with the 
procedure of  recording the  post-operative pain scores 
using a Visual analogue scale (VAS) -chart, which consists 
of  a 10cm line with 0 equalling “no pain” and 10 equal-
ling “worst pain possible”.
A flow diagram of  patient distribution is shown in figure 
1.
This study was undertaken at the Aga Khan University 
hospital, Nairobi operating theatres, ASA physical status 
I-III patients scheduled for lower limb orthopaedic sur-
gery and were randomized to either  receive 2.6mls of  
0.5% hyperbaric bupivacaine with 0.4mls (20mcg) fentan-
yl or 2.6mls of  0.5% hyperbaric bupivacaine with 0.4mls 
(2mg) midazolam intrathecally at L3-S1 interspace. The 
anaesthesiologist conducting the procedure (principal 
investigator or research assistant) received together with 
the data entry form the randomization group and admin-
istered the study drugs as per randomization group.
On arrival to the operating theatres, standard monitoring 
was applied with automated non-invasive blood pressure 
measurement, electrocardiography and pulse oximetry, 
with the objective of  obtaining the baseline cardiovascu-
lar parameters. Prior to performing the spinal anaesthesia 
the patient would receive 500mls of  Ringers lactate solu-
tion intravenously
After a local infiltration of  2ml 2% lidocaine solution, 
a midline puncture with a 25 French gauge pencil point 
needle was performed at L3-L4, L4-L5 interspace, with 
the patient in the sitting or lateral decubitus position. Af-
ter obtaining free flow of  CSF, the study drugs previously 
prepared by anaesthesiologist as per randomization group 
were administered. Patients were then turned supine and 
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the sensory block level to both light touch and tempera-
ture were checked at 2.5 minute intervals until there was 
no change in 3 consecutive readings, the time of  maximal 
block was documented as the time of  onset of  the block. 
After this, the anaesthesiologist assessed the modified 
Bromage motor score (1 - able to move hip, knee and 
ankle; 2 – unable to move hip, able to move knee and 
ankle; 3 - unable to move hip and knee, able to move 
ankle; 4 - unable to move hip, knee and ankle).Surgery 
was allowed to commence as soon as the sensory block 
height to light had been tested pre-incision and reached 
the desired level. Subsequently the sensory block height, 
the Bromage score, the vital signs (non-invasive blood 
pressure, heart rate and oxygen saturation) and VAS were 
determined and recorded every hour.
If  pain or discomfort was felt, analgesia options of  either 
GA or supplementary analgesia with IV adjuncts such as 
fentanyl 1-2mcg/Kg and IV paracetamol 1g was given.
Hypotension (defined as a reduction in MAP of  more 
than 20% from baseline determined just before the ad-
ministration of  regional anaesthesia) was treated with 
ephedrine boluses of  6 mg. Bradycardia (defined as heart 
rate less than 60bpm) was treated with atropine. The pres-
ence of  intraoperative nausea, vomiting, pruritus, and 
shivering was also noted and treated appropriately; res-
cue antiemetic drugs using a combination of  IV ondan-
setron 4mg or granisetron 1mg were administered at the 
discretion of  the anaesthesiologist. Other complications 
that patients developed were noted (inadequate blocks, 
conversion to general anaesthesia, bradycardia, pruritus, 
hypotension, respiratory discomfort, ephedrine use, col-
loids use, and crystalloid use). All the complications that 
occurred were noted by the anaesthesiologist. At the end 
of  surgery, the patient received IV paracetamol 1g and 
IM diclofenac 75mg.
The principal investigator together with the research as-
sistants followed up the patients in the wards with hourly 
monitoring of  the VAS, Bromage score, sensory block 
height and vital signs (non-invasive blood pressure, heart 
rate and arterial oxygen saturation). The time of  request 
first analgesia was taken as the first time the patient re-
quested for analgesia or the VAS >/= 4.
Intraoperative data was collected by the principal inves-
tigator or trained research assistant using the data collec-
tion form.
Upon collection data was entered into the statistical soft-
ware (SPSS version 15) on the same day in a coded form 
and saved, awaiting analysis. All data entered was verified 
by the principal investigator.
Data analysis was undertaken using the SPSS version 15 
with the input of  a statistician who had been involved 
since the beginning of  the study.
Descriptive statistics were used to compare patients’ char-
acteristics in terms of  age, sex, height, weight.  Student’s 
T test was used to compare if  the 2 sample sizes were sta-
tistically different. The unpaired student’s t test was used 
to compare the differences between duration of  effective 
analgesia and VAS at administration of  rescue analgesia
The Chi test was used to compare the proportions of  var-
ious complications between the two groups. Survival time 
analysis (Kaplan Meir) was used to analyze the duration 
of  effective analgesia. Log rank test was used to compare 
duration of  effective analgesia.
A P value of  < 0.05 was considered statically significant.
 
Results
Data collection was carried out over four months, Octo-
ber 2012 to January 2013. A total of  40 participants were 
recruited from the outpatient clinic and surgical wards 
and randomised for the study. All the participants recruit-
ed were followed up and included in the data analysis, 
twenty in each arm.
Age, weight, height, ASA status were similar in both 
groups. There was a significant difference in the number 
of  males and females in either group (Table 1). There was 
no significant difference in age, weight, height and ASA 
status of  the patients.
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Table 1: Patient’s baseline characteristics 
 
  Midazolam Fentanyl ‘P’ 
Age 44.6 (18.1) 52.6(17.6) 0.164 
Height 163.9(15.9) 158.3(19.6) 0.324 
Weight 75.8(11) 76.1(12.7) 0.947 
ASA status 2.1(0.9) 2(0.9) 0.713 
Sex( Male) 7 15 0.002 
Sex (Female) 13 5 0.004 
Note: Mean age, height, weight and ASA are presented as Mean +/_SD; t - test used for analysis 
The majority of  the procedures conducted were knee ar-
throscopy contributing to 32.5% of  procedures conduct-
ed and the least was above knee amputation that contrib-
uted 2.5% of  the total surgical procedures done. Table 2 
shows the distribution of  the procedures in each group.
The duration of  effective analgesia in the midazolam 
group 384.05minutes as compared to the fentanyl group 
342.6 minutes; this was not significant (‘P’ -0.4047). 
Table 2: Types of surgical procedures 
 
Type of surgery Midazolam group Fentanyl group Totals 
Knee arthroscopy 8(40%) 5(25%) 13(32.5%) 
Knee replacement 4(20%) 3(15%) 7(17.5%) 
Hip replacement 0 3(15%) 3(7.5%) 
ORIF femur 3(15%) 3(15%) 6(15%) 
ORIF Tibia 1(5%) 1(5%) 2(5%) 
ORIF ankle 3(15%) 5(25%) 8(20%) 
Above knee 
amputation 
1(5%) 0 5(2.5%) 
Total 20 20 40(100%) 
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The time to onset was significantly longer in midazolam 
group 17.1 minutes as compared to the fentanyl group 
13.2 minutes (‘P - 0.023’). The visual analogue score at 
rescue was significantly lower in the midazolam group 
5.55 as compared to the fentanyl group 6.35 (‘P - 0.043’) 
(Table 3).
Table 3: Primary outcome 
 
Variable Midazolam 
Mean (sd) 
(CI) 
Fentanyl 
Mean (sd) 
(CI) 
Mean difference 
(CI) 
‘P’ 
Time to 
maximum block 
(minutes) 
17.1(6.5) 
(14.08-20.12) 
13.2(3.8) 
(13.8-14.9) 
3.95(0.6-7.3) 0.023 
VAS at rescue 5.55(1.099) 
(5.04-6.06) 
6.35(1.31) 
(5.74-6.96) 
0.8(0.02-1.57) 0.043 
Duration of 
effective 
analgesia 
384.05(158.99) 
(309-458) 
342.6(152.04) 
(271-413) 
41.45(0-141) 0.4047 
  
Time to maximum block, VAS at rescue and duration of effective analgesia are presented as Mean 
+/_SD and confidence intervals; t - test used for analysis 
Intraoperatively there was a higher incidence of  pruritus 
in the fentanyl group 57.9% as compared to none in the 
midazolam group (‘p <0.001’).  There was no significant 
difference in the intraoperative incidences of  nausea/
vomiting and sedation in the midazolam group as com-
pared to fentanyl group (table 4). 
Table 4: incidence of intraoperative complications 
 
Complications Midazolam Fentanyl ‘P’ 
Nausea / Vomiting 2(10%) 4(20%) 0.661 
Hypotension 2(10%) 2(10%) 1.0 
Pruritus 0 11(57.9%) <0.001 
Sedation 4(20%) 1(5%) 0.342 
Respiratory depression 0 0 
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Post operatively there was also no significant difference in the incidence of  side effects (Table 5).
Table 5: Incidence of post-operative complications 
 
Complications Midazolam Fentanyl ‘P’ 
Urinary retention 1(5%) 3(15%) 0.605 
Headache 5(25%) 5(25%) 1.0 
Dizziness 4(20%) 4(20%) 1.0 
Nausea / Vomiting 1(5%) 4(20%) 0.106 
Respiratory depression 0 1(5%) 
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Figure 1: Flow diagram of  patient’s
Discussion
In this single blind randomized control study of  40 pa-
tients undergoing lower limb orthopaedic surgery under 
spinal anaesthesia, there was no statistically significant 
difference between the duration of  effective analgesia 
of  adjuvant 2mg intrathecal midazolam as compared to 
20mcg intrathecal fentanyl.
The rationale for the use of  intrathecal midazolam fo-
cuses on the awareness that it is an agonist at the ben-
zodiazepine binding site, a subunit of  the pentameric-
gamma-aminobutyric acid (GABA A) receptor. Agonist 
occupancy of  the benzodiazepine binding site enhances 
the activity of  GABA at the GABA A receptor. This re-
ceptor is a chloride ionophore that, when activated, typi-
cally stabilises the transmembrane potential at, or near, 
the resting potential. In neurons, this typically serves to 
decrease excitability. Intrathecal benzodiazepine-induced 
analgesia is spinally mediated. Binding sites are GABA re-
ceptors, abundantly present in the dorsal root nerve cells, 
with the maximum concentration found within lamina II 
of  the dorsal nerve cells, a region that plays a prominent 
role in processing nociceptive and thermoceptive stimu-
lation21. The present cumulative experience with intrathe-
cal midazolam across species broadly confirms the safety 
thereof, the analgesic activity of  the molecule and its ben-
zodiazepine pharmacology, and the lack of  irreversible 
effects22.
In the present study it was observed, that there is no sta-
tistically significant difference in the duration of  effective 
analgesia, this finding is different from that of  a previ-
ous study comparing the two drugs20.  This relationship 
may be explained by another study comparing19 different 
doses of  intrathecal midazolam that found that 2mg dose 
of   adjuvant midazolam had a longer duration of  effec-
tive analgesia as compared to the 1mg dose. The confi-
dence intervals obtained for the primary outcome were 
very wide, since the study was powered for this outcome, 
the reason could have been due to equivalence but the 
study was not powered to determine this.
The ‘P’ obtained for the time to maximum block and VAS 
score showed there may be a difference but this was not 
statistically significant since there was an overlap of  the 
confidence intervals in duration and pain score obtained 
between the two groups. In addition, the study was not 
powered to measure this difference and assess its signifi-
cance.  
Safari el al while studying the effect of  adjuvant 1 mg 
midazolam compared with 25 mcg fentanyl on the dura-
tion of  spinal anaesthesia with 0.5% bupivacaine in opi-
um abusers concluded midazolam is more effective than 
fentanyl in such cases. Our study further confirms their 
findings30.  
The incidence of  nausea and vomiting noted in this study 
was determined to be 5% both intra-operatively and 
post-operatively and this was lower than that of  intrathe-
cal fentanyl; these findings are similar to one done23 to 
compare fentanyl, midazolam and placebo and found the 
highest reduction in incidence of  nausea was in the mid-
azolam group. Our findings were comparable to those Ho 
et al27 who in their meta-analysis of  the use of  intrathecal 
midazolam to improve postoperative analgesia concluded 
that it appeared to improve perioperative analgesia and 
reduce nausea and vomiting in caesarean delivery.
The incidence of  respiratory depression in the present 
study was 5% of  patients in the fentanyl group as com-
pared to that of  previous studies that found an incidence 
of  up to 3.4%13. This may be explained by the fewer num-
ber of  patients who were recruited in our study and the 
5% incidence is attributable to one patient who devel-
oped respiratory depression both intra-operatively and 
post-operatively. The mechanism of  intrathecal opioid in-
duced respiratory depression is due to the rostral spread.
Various studies have found different incidences of  seda-
tion following intrathecal midazolam. In the study con-
ducted by Talwar and colleagues20, the incidence of  seda-
tion was higher in the intrathecal fentanyl group than in 
the intrathecal midazolam group. Dureja et al while assess-
ing the efficacy of  intrathecal midazolam with or without 
methylprednisolone for management of  post-herpetic 
neuralgia involving lumbosacral dermatomes found a 
mild degree of  sedation in the midazolam group28. In the 
present study, the incidence of  sedation was higher in the 
midazolam group than in the fentanyl group. This differ-
ence may have occurred due the higher intrathecal dose 
of  midazolam (2mg) that was used in the present study.
Niv and colleagues conducted neurotoxicologic studies 
in animals by studying histologic and vascular lesions in 
animal spinal cord samples, indicating the neurotoxic ef-
fects of  intrathecal midazolam24. Therefore, they advised 
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against the use of  intrathecal midazolam in humans. Sub-
sequent studies in humans9,25,29, found no adverse neuro-
logical symptoms in those who had received intrathecal 
midazolam. In agreement with these studies, the present 
study observed no significant adverse neurological effects 
in any patient during the study period. Further current 
reports suggest that midazolam in a dose of  1-2mg at a 
concentration not exceeding 1mg/ml is not accompanied 
by an increase in adverse events22.
 
Limitations. 
One of  the limitations of  this study was that despite ran-
domization there was heterogeneity as concerns the na-
ture of  the procedures, these procedures varied from ar-
throscopy to total hip replacement. This therefore meant 
the difference in the extent of  tissue damage and thereby 
the nociceptive input was large and may have had an ef-
fect on the duration of  effective analgesia.
Another limitation is the lack of  standardization as con-
cerns the use of  local anaesthetic infiltration at the surgi-
cal site. This may have resulted the longer duration of  ef-
fective analgesia for certain procedures due to the routine 
use of  local anaesthetic infiltration at the end of  surgery 
by some surgeons.
Conclusion
On the basis of  the results of  this study, there was no 
difference in the duration of  effective analgesia between 
adjuvant intrathecal 2mg midazolam as compared to in-
trathecal 20micrograms fentanyl for patients undergoing 
lower limb orthopaedic surgery.
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